LTFS
DRNA

Ladenburg Thalmann Financial Services’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$7K Buy
305
+252
+475% +$5.07K ﹤0.01% 4668
2019
Q3 		$1K Buy
+53
New +$758 ﹤0.01% 5207
2018
Q1 		– Sell
-100
Closed -$1K – 5254
2017
Q4 		$1K Buy
+100
New +$736 ﹤0.01% 4966

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Ladenburg Thalmann Financial Services's DRNA Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Dicerna Pharmaceuticals, Inc. (DRNA) stake by 475% in Q4 2019, buying an estimated $5.07K and bringing the position to 305 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #4668.

Ladenburg Thalmann Financial Services first reported a position in DRNA in Q4 2017 and has held it in 3 quarters since. 169 funds tracked by Wall St. Rank hold DRNA as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 305 shares of Dicerna Pharmaceuticals, Inc. worth $7K as of Q4 2019.
  • Ladenburg Thalmann Financial Services bought 252 Dicerna Pharmaceuticals, Inc. shares in Q4 2019, an estimated $5.07K.
  • Dicerna Pharmaceuticals, Inc. made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4668 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2017 and has held it in 3 quarters since.
  • 169 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.